This page shows the latest NMOSD news and features for those working in and with pharma, biotech and healthcare.
Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna. Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its ... Currently, Viela has one US Food and Drug
It is also indicated for use in adult NMOSD patients who are AQP4 antibody positive. ... The new NMOSD treatment was originally designed by Roche’s Japanese subsidiary Chugai, using novel recycling antibody technology.
This group reflects a real-world population of adolescents and adults with NMOSD who tend to experience a more severe disease course. ... It was approved to treated NMOSD in adult patients who are AQP4 antibody positive.
Meanwhile, another emerging rival in the NMOSD category is Viela Bio, whose inebilizumab was filed for approval with the FDA earlier this year. ... Roche says NMOSD affects over 10, 000 people in Europe, 15, 000 people in the US and 'up to hundreds of
in 2018, thanks to new indications such as generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) that have broadened its reach.
NMOSD disproportionately affects young women in the prime of their lives, with the average age of onset just 39 years. ... It became the first FDA-approved treatment for NMOSD at that time, but competitors, including Roche, are hot on its heels.
More from news
Approximately 5 fully matching, plus 6 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...